Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine.[2] It was introduced in 1965. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results"[3] had not yet been confirmed nor denied in controlled trials.
 | |
| Combination of | |
|---|---|
| Phenobarbital | Barbiturate |
| Levopropylhexedrine | Sympathomimetic |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.022.278 |
  (what is this?) (verify) | |
Potency
edit100 mg of barbexaclone is equivalent to 60 mg of phenobarbital.[2]
References
edit- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ a b Shorvon S, Perucca E, Engel Jr J (23 September 2015). The Treatment of Epilepsy. Wiley. pp. 1706–1707. ISBN 978-1-118-93699-3.
- ^ Salles Barbosa MF (September 1978). "[Barbexaclone in the treatment of cerebral dysrhythmia]". Arquivos de Neuro-Psiquiatria. 36 (3): 245–249. doi:10.1590/s0004-282x1978000300009. PMID 28716.
Further reading
edit- Shorvon SR, Fish DR, Perucca E, Dodson WE, eds. (2004). The Treatment of Epilepsy (2nd ed.). Published by Blackwell. p. 472. ISBN 0-632-06046-8.
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |